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ABSTRACT 
 
Objectives: We analyzed MAPK, Akt, and STAT3 pathway expression and 
BRAF gene status in oral epithelial precursor lesions (OEPLs) and oral 
squamous cell carcinoma (OSCC).  
Study design: Fifteen leukoplakia (LP), 15 low-grade epithelial dysplasia 
(LD), 15 high-grade epithelial dysplasia (HD), and 132 OSCC specimens 
were immunohistochemically examined for KRAS, HRAS, NRAS, BRAF, 
BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 expression. BRAF 
mutations were detected by high resolution melting (HRM) analysis, DNA 
sequencing, and immunohistochemistry.  
Results: Immunoreactivity for these molecules predominantly occurred in 
regions OEPL basal to prickle layers and in most OSCC cells. KRAS and 
NRAS expression was lower in OSCC than in OEPLs, whereas BRAF-V600E 
incidence was higher in OSCC than in OEPLs. pERK1/2 expression was 
higher in HD than in LP. pAkt and pmTOR expression was lower in LP than 
in other lesions. Correlations between these markers and clinicopathological 
variables were also noted. Based on HRM, BRAF mutations were suspected 
in seven OEPLs and 34 OSCCs; subsequent DNA sequencing confirmed 
mutations in one LD, one HD, and five OSCC specimens, which were 
associated with BRAF-V600E immunoreactivity.  
Conclusion: MAPK, Akt, and STAT3 pathways might play diverse roles in 
oral carcinogenesis. BRAF mutations are relatively rare but important 
aberrations for OSCC.  
3 
 
INTRODUCTION 
 
Oral squamous cell carcinoma (OSCC) comprises a subset of head and neck 
squamous cell carcinoma (HNSCC) that involves the tongue, gingiva, buccal 
mucosa, floor of the mouth, and hard palate. OSCC is considered to be the 
sixth most common oral cancer worldwide.1,2 Despite improvements in 
treatment strategies over the past few decades, including surgery and 
radiotherapy, with or without chemotherapy, the 5-year survival rates 
(approximately 50%) remain lower than those of most major cancers.3,4 SCC 
can be superficial as well as deep, destroying oral cavity tissues and 
metastasizing to regional lymph nodes or distant organs, most frequently the 
lung.5  
 Among the oral potentially malignant disorders, leukoplakia is the most 
commonly encountered lesion and can show histological evidence of 
hyperkeratosis/squamous cell hyperplasia with or without epithelial 
dysplasia. Epithelial dysplasia is classified according to the World Health 
Organization (WHO) classification of tumors of the oral cavity and mobile 
tongue as follows: low-grade and high-grade based on the presence and 
severity of cell atypia and structural aspects of the epithelium. 
Histopathological evaluation of the grade of epithelial dysplasia is the most 
common method used to ascertain malignant potential in individuals with 
oral epithelial precursor lesions (OEPLs). Further, the frequency of 
carcinomatous changes in these oral epithelial precursor lesions has been 
reported to vary from 6.6% to 36%.2,6,7 
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 Several growth factors and their receptors, such as epidermal growth factor 
receptor (EGFR), have been studied as prognostic biomarkers for many 
epithelial malignancies. Overexpression of EGFR is associated with poor 
prognosis in patients with HNSCC.8,9 Moreover, the downstream signaling 
pathways affected by activation of these growth factors and their receptors 
include RAS/RAF/ERK, PI3K/Akt/mTOR, and STAT3.8,10,11 
The MAPK pathway is a very important signaling pathway for cell 
proliferation, migration, and survival. RAS GTPase are monomeric G 
proteins with a molecular mass of 21 kDa that cycle between GTP-bound 
active and GDP-bound inactive states. The RAS subfamily consists of KRAS, 
HRAS, and NRAS.12,13 Activation of RAS initiates a multi-step 
phosphorylation cascade that leads to the activation of RAF kinase. The RAF 
subfamily consists of three highly conserved serine/threonine kinases, 
namely ARAF, BRAF, and CRAF.14 Among these, the genes encoding B and C 
isoforms, and especially BRAF, were shown to be associated with mutations 
in cancer.15 Mutations of BRAF have been described in some types of cancers, 
especially malignant melanoma, papillary thyroid cancer, and colorectal 
cancer.15,16 More than 90% of BRAF mutations consist of a glutamic acid to 
valine substitution at amino acid position 600, referred as BRAF c.1799 T>A 
(BRAF-V600E). This substitution leads to constitutive activation of the 
encoded protein.17 Activated RAFs phosphorylate the MEK kinase, which 
finally activates extracellular ERK1/2.18 The latter signaling molecule is 
activated by phosphorylation at both tyrosine and threonine residues. 
Phosphorylated ERK1/2 (pERK1/2) subsequently translocates to the nucleus 
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and regulates transcriptional programs related to cell proliferation.19 In 
HNSCC, levels of pERK1/2 expression were found to correlate with increased 
nodal metastasis, proliferative rate, and recurrence.8 
The PI3K/Akt/mTOR pathway also plays a fundamental role in 
tumorigenesis.9 This signaling cascade begins with PI3K activation at the 
cell membrane, followed by Akt activation. Akt is a serine/threonine protein 
kinase that requires phosphorylation for activation. Phosphorylated Akt 
(pAkt) regulates the activity of numerous downstream molecules including 
mTOR, which has emerged as an essential effector of cell signaling 
pathways.20,21 mTOR is also a serine/threonine protein kinase that requires 
phosphorylation for activation. pAkt and phosphorylated mTOR (pmTOR) 
translocate from the cytoplasm to the nucleus leading to the transcription of 
genes responsible for cell cycle progression and cellular proliferation.21,22  
STAT3 is a member of the STAT family, which participates in many 
physiological processes, such as cell proliferation, survival, and 
differentiation.23 Constitutive activation of STAT3 has been demonstrated in 
several human cancers including lung cancer, breast cancer, colon cancer, 
and HNSCC.10,23 STAT3 tyrosine phosphorylation can be induced by 
stimulation via upstream receptor and/or nonreceptor kinases including 
EGFR, IL-6, JAK, and Src. Phosphorylated STAT3 (pSTAT3) dimerizes and 
translocates to the nucleus to regulate the transcription of the target genes.24 
Recent studies have shown that the expression of pSTAT3 is associated with 
lymph node metastasis, recurrence, and poor prognosis in HNSCC.24,25  
 The present study was designed to assess the role of MAPK, Akt, and 
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STAT3 pathways in OSCC and OEPLs. In addition, mutations of the BRAF 
gene and BRAF-V600E protein expression were analyzed in these 
specimens. 
 
 
MATERIALS AND METHODS 
 
The study protocol was reviewed and approved by the Research Ethics 
Committee of Tohoku University Graduate School of Dentistry (2017-3-2).  
 
Clinicopathological characteristics 
Specimens were surgically removed from 132 patients with primary OSCC 
and 45 patients with OEPLs in the Department of Oral and Maxillofacial 
Surgery, Tohoku University Hospital from 2012 through 2016. All OSCC 
patients had never received chemotherapy or radiotherapy before surgery. 
The TNM disease stage was classified according to the Union for 
International Cancer Control (UICC) system.26  None of the OEPLs patients 
were diagnosed as OSCC at any of the sites before surgery or progressed to 
OSCC. 
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Sample preparation 
Tissue samples were fixed in 10% buffered formalin for several days and 
embedded in paraffin. The tissue blocks were sliced into 4-μm-thick sections 
for routine histological examination and subsequent immunohistochemical 
and genetic analyses. The tumor histological grade was determined 
according to the World Health Organization classification.2 The mode of 
tumor invasion was classified as previously described 27; carcinoma grade 
was 2, 3, 4C, and 4D. The invasion depth was classified into microinvasion 
and invasion within the mucosal tissue and into the submucosal tissue. 
Lymphoplasmacytic infiltration was determined on hematoxylin and eosin 
stained specimens according to the Anneroth classificassion.2 
OEPLs pathological diagnoses were made according to the WHO 
classification of tumors of the oral cavity and mobile tongue.2 In all, fifteen 
patients had leukoplakia without epithelial dysplasia (hyperkeratosis or 
squamous cell hyperplasia; LP), 15 had low-grade epithelial dysplasia (mild 
to moderate dysplasia; LD), and 15 had high-grade epithelial dysplasia 
(severe dysplasia or carcinoma in situ; HD).  
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Immunohistochemistry for KRAS, HRAS, NRAS, BRAF, BRAF-V600E, 
pERK1/2, pAkt, pmTOR, and pSTAT3 expression 
Tissue sections were deparaffinized and immersed in methanol with 0.3% 
hydrogen peroxide. The sections were heated in 0.01 M citrate buffer (pH 6.0; 
for HRAS and NRAS) or 1 mM ethylenediamine tetraacetic acid (EDTA) 
buffer (pH 9.0; for BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and 
pSTAT3) for 10 min by autoclaving (121 °C, 2 atm). Specimens were then 
incubated with primary antibodies at 4 °C overnight. The applied antibodies 
were mouse anti-KRAS monoclonal (ProteinTech, Chicago, IL, USA; isotype 
IgG1, diluted at 1:100), rabbit anti-HRAS polyclonal (ProteinTech; isotype 
IgG, diluted at 1:50), rabbit anti-NRAS polyclonal (ProteinTech; isotype IgG, 
diluted at 1:50), rabbit anti-BRAF monoclonal (Abcam, Cambridge, UK; 
isotype IgG, diluted at 1:250), mouse anti-BRAF-V600E monoclonal (Spring 
Bioscience, Pleasanton, CA, USA; isotype IgG2a, diluted at 1:100), rabbit 
anti-ERK1 (phospho Thr202 + Tyr204 ) / ERK2 (phospho Thr185 + Tyr187) 
monoclonal (Abcam; isotype IgG1, diluted at 1:100), rabbit 
anti-phospho-Akt1/2/3 (Thr308) polyclonal (Santa Cruz, Dallas, TX, USA; 
isotype IgG, diluted at 1:100), rabbit anti-phospho-mTOR (Ser2448) 
polyclonal (Signalway Antibody, Pearland, TX, USA; isotype IgG, diluted at 
1:100), and rabbit anti- phospho-STAT3 (Tyr705) monoclonal (Abcam; isotype 
IgG, diluted at 1:100). The sections were then incubated with 
peroxidase-conjugated anti-mouse IgG (for KRAS and BRAF-V600E) or 
anti-rabbit IgG (for HRAS, NRAS, BRAF, pERK1/2, pAkt, pmTOR, and 
pSTAT3) polyclonal antibodies (Histofine Simple Stain MAX-PO; Nichirei, 
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Tokyo, Japan) for 45 min, and reaction products were visualized by 
immersing the sections in 0.03% diaminobenzidine (DAB) solution 
containing 2 mM hydrogen peroxide for 3 to 5 min. Nuclei were lightly 
stained with Mayer’s hematoxylin. Slides for pERK1/2 were also exposed 
using the streptavidin–biotin method (Histofine SAB-PO kit; Nichirei). For 
antibody negative control experiments, the serial sections were treated with 
phosphate-buffered saline (PBS), normal rabbit IgG, mouse anti-OPD4 
(CD45RO) monoclonal antibody (Dako, Glostrup, Denmark; isotype IgG1), 
and mouse anti-alpha-smooth muscle actin monoclonal antibody (Dako; 
isotype IgG2a) instead of primary antibodies and were confirmed to be 
unstained. 
 
Evaluation of immunohistochemical results 
 Immunohistochemical reactivity for KRAS, HRAS, NRAS, BRAF, pERK1/2, 
pAkt, pmTOR, and pSTAT3 was evaluated and classified into two groups as 
follows: (+) positive (reactive at the same level as adjacent normal part) and 
(++) strongly positive (strongly reactive as compared to staining in the 
adjacent normal part). BRAF-V600E antibody staining was scored as (+) 
positive when the tumor cells showed clear cytoplasmic staining, and (−) 
negative when there was no staining or only nuclear dot staining. Cases 
were scored as (±) weak positive or ambiguous if immunostaining could not 
be evaluated as positive or negative.   
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DNA extraction 
 DNA was extracted from 10-μm-thick sections of paraffin-embedded tumor 
tissue blocks in 80 μL of elution buffer using the MagNa Pure LC DNA 
Isolation Kit II (Roche, Mannheim, Germany), after deparaffinization with 
xylene and overnight proteinase K digestion. 
 
High resolution melting (HRM) analysis 
 BRAF mutations were detected by HRM analysis followed by 
pyrosequencing on a LightCycler® 480 Instrument (Roche). HRM analysis 
was performed using 1 μL of genomic DNA, 2 μL of 2.5 mM MgCl2, 10 μL of 
Master Mix, 0.4 μL of primer (10 μM each), and 6.2 μL of dH2O in a final 
reaction volume of 20 μL. Thermocycling conditions for PCR included one 
cycle denaturation at 95 C for 10 min and 50 cycles consisting of 
denaturation at 95C for 20 s, annealing at 55 C for 20 s, and extension at 
72 C for 15 s, with subsequent cooling at 40 C for 30 s. Primer sequences 
were as follows: forward 5′- CATAATGCTTGCTCTCTGATAGGAAA -3′ and 
reverse 5′- TCAGCACACATCTCAGGGCCAAA -3′. HRM curve analysis was 
performed using LightCycler® 480 Gene Scanning Software Version 1.5 
(Roche). Normalized and temperature-adjusted melting curves of test 
samples and wild type controls were compared, and samples with an 
aberrant melting pattern were judged to harbor a somatic mutation. 
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Direct DNA sequencing for BRAF gene mutations 
 Amplified products of mutation-positive or ambiguous samples, as detected 
by HRM analysis, were recovered from the plate and purified with the 
Wizard® SV Gel and PCR Clean-up System (Promega, Madison, WI, USA); 
direct DNA sequencing was performed using an ABI Prism 3100 Genetic 
Analyzer (Applied Biosytems, Carlsbad, CA, USA). 
 
Statistical analysis 
 The statistical significance of differences in immunohistochemical reactivity, 
HRM analysis, DNA sequencing, and correlation analyses were tested by the 
Mann–Whitney U-test for differences between two groups or the Kruskal–
Wallis test for differences among three or more groups. P values less than 
0.05 were considered to indicate statistical significance. 
 
 
RESULTS 
Patient characteristics 
Details of patient characteristics were shown in Table 1. Ages ranged from 
25 to 95 years (mean, 66.8 years); 70 were men and 62 were women. 
Seventy-one carcinomas were located in the tongue, 11 in the upper gingiva, 
24 in the lower gingiva, two in the hard palate, 11 in the buccal mucosa, 10 in 
the floor of the mouth, and three in the lower lip, respectively. The T 
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classifications were T1 for 40 cases, T2 for 41, T3 for 17, and T4 for 34, the N 
classifications were N0 for 100 cases, N1 for nine, N2 for 22, and N3 for one; 
M classifications were M0 for 126 cases and M1 for six cases. According to 
overall TNM stage grouping, 36 patients had stage I, 38 had stage II, 20 had 
stage III, and 38 had stage IV disease. During the follow-up period (23−66 
months), local recurrence occurred in 19 patients and post-operative regional 
lymph node metastasis was noted in 16 patients. Nineteen patients died of 
OSCC and two died of unrelated causes. The histological grade was 
well-differentiated in 110 of the patients, moderately -differentiated in 18 of 
the patients, and poorly-differentiated in 4 of the patients. The degree of 
stromal lymphocytic reaction was classified as slight for 12 specimens, 
moderate for 118, and severe for two. The mode of tumor invasion grade was 
2 for 17 specimens, 3 for 85, 4C for 24, and 4D for 6. The invasion depth was 
microinvasion for 36, invasion within the mucosal tissue for 51, and the 
submucosal tissue for 45 tumors, respectively. 
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Immunohistochemical reactivity of KRAS, HRAS, NRAS, BRAF, 
BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 in OEPLs and OSCC 
The results of immunohistochemical studies of KRAS, HRAS, NRAS, BRAF, 
BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 expression in OEPLs 
and OSCC are summarized in Table I and Figures1−3.  
KRAS immunohistochemical reactivity was detected in the cytoplasm, with 
occasional membrane localization in epithelial cells of OEPLs (Figure 1F, 1G, 
and 1H), and in the cytoplasm of most OSCC cells (Figure 1I and 1J). KRAS 
immunohistochemical reactivity was significantly decreased in OSCC 
compared to that in LP (P < .001), LD (P < .001), and HD (P < .001) (Table I). 
HRAS and NRAS immunoreactivity were detected in the cytoplasm of 
epithelial cells of OEPLs and OSCC (Figure 1K−1O, 1P−1T). HRAS and 
NRAS reactivity was detected in the basal and parabasal cell layer of OEPLs 
(Figure 1K−1M, 1P−1R) and in most OSCC cells (Figure 1N, 1O, 1S, and 1T). 
NRAS immunohistochemical reactivity was significantly decreased in OSCC 
compared to thay in LP (P < .001), LD (P < .001), and HD (P < .001) (Table I). 
Moderate to strong cytoplasmic BRAF staining was observed in basal cell 
and prickle cell layers of OEPLs (Figure 2F−2H) and in most OSCC cells 
(Figure 2I and 2J). Weak cytoplasmic BRAF-V600E reactivity was observed 
in basal to prickle cell layers of one LD and one HD case. For OSCC 
specimens, weak cytoplasmic staining was noted in most carcinoma cells in 
29 cases and moderate to strong cytoplasmic staining was observed in most 
carcinoma cells in five cases. Immunohistochemical reactivity for 
BRAF-V600E was significantly increased in OSCC compared to that in LP (P 
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< .05; Table I). pERK1/2 immunoreactivity was detected in the cytoplasm 
and nuclei of epithelial cells of OEPLs and OSCC. pERK1/2 reactivity was 
detected in basal and parabasal cell layers of OEPLs (Figure 2P−2R) and in 
most OSCC cells (Figure 2S and 2T). Immunohistochemical reactivity for 
pERK1/2 was significantly enhanced in HD compared to that in LP (P < .05; 
Table I). 
pAkt and pmTOR immunoreactivity was detected in the cytoplasm and 
nuclei of epithelial cells of OEPLs and OSCC (Figure 3F−3J, 3K−3O). pAkt 
and pmTOR reactivity, with co-localization, was detected in basal and prickle 
cell layers of OEPLs (Figure 3K−3M, 3P−3R). OSCC exhibited pAkt and 
pmTOR reactivity in most carcinoma cells (Figure 3N, 3O, 3S, 3T). 
Immunohistochemical reactivity for pAkt was significantly enhanced in 
OSCC compared to that in LP (P < .01; Table I). Further, pmTOR reactivity 
was significantly decreased in LP compared to that in LD (P < .001), HD (P 
< .001), and OSCC (P < .001) (Table I). pSTAT3 immunoreactivity was 
detected in the cytoplasm and nuclei of epithelial cells of OEPLs and OSCC 
(Figure 3P−3T). pSTAT3 reactivity was detected in basal and prickle cell 
layers of OEPLs (Figure 2P−2R) and OSCC exhibited pSTAT3 reactivity in 
most carcinoma cells (Figure 3S and 3T). 
 
Correlation between clinicopathological variables and KRAS, HRAS, NRAS, 
BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 
immunoreactivity in OSCC 
KRAS, HRAS, NRAS, BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and 
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pSTAT3 immunohistochemical reactivities in 132 OSCC specimens were 
compared to underlying clinicopathological variables (Table II and III).  
The expression of KRAS in tumors was higher in patients with the following 
clinicopathological characteristics: patients in their 80s rather than patients 
in their 40s (P < .001), 60s (P < .001), and 70s (P < .001); and males rather 
than females (P < .001) (Table II). A weak correlation between KRAS 
expression and M classification was also found without reaching statistical 
significance (P = .060). KRAS expression was also associated with tumor site 
based on an analysis of variance (P < .05), but significant differences were 
not noted based on multivariate analysis (Table II). No clinicopathological 
variables were found to correlate with HRAS expression. The expression of 
NRAS in tumors was higher in patients with the following 
clinicopathological characteristics: patients in their 80s rather than patients 
in their 50s (P < .001), 60s (P < .001), and 70s (P < .01); males rather than 
females (P < .001); tongue rather than lower gingiva (P < .05) (Table II).  
A weak correlation between BRAF expression and sex was also found 
without reaching statistical significance (P = .067; Table II). Further, the 
expression of BRAF-V600E was higher in cases with post-operative 
metastasis (P < .05) (Table II). In addition, the expression of pERK1/2 was 
higher in tumors with the following clinicopathological characteristics: 
female patients (P < .05); T4 cases rather than T2 cases (P < .01), and TNM 
stage IV cases rather than TNM stage II cases (P < .01) (Table II).  
The expression of pAkt was higher in T4 cases than in T2 cases (P < .05) 
and in cases without post-operative metastasis (as compared to those with 
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metastasis; P < .05) (Table II). Moreover, the expression of pmTOR was 
higher in grade 2 and 4C mode of invasion cases, as compared to that in 
grade 4D cases (P < .05; Table III). In addition, the expression of pSTAT3 was 
decreased in tumors with the following clinicopathological characteristics: 
cases without recurrence (as compared to those with recurrence; P <.05); 
hard palate rather than tongue (P < .01), upper gingiva (P < .05), lower 
gingiva (P < .01), buccal mucosa (P < .01), and lower lip (P < .05) (Table II); 
cases of microinvasion rather than those with mucosal (P < .05) and 
submucosal invasion (P < .05) (Table III).  
 
Identification of BRAF mutations using HRM, direct DNA sequencing, and 
IHC in OEPLs and OSCC 
The results of IHC assays, HRM analysis, and direct sequencing of BRAF 
mutations are shown in Table IV and Figure 4. A total of 177 patients were 
analyzed for BRAF mutations by both HRM analysis and IHC assays, 
including 132 cases of OSCC, 15 cases of LP, 15 cases of LD, and 15 cases of 
HD. Among the 177 cases, IHC staining was positive in 36 cases including 
one case (of 15, 6.7%) of LD, one case (of 15, 6.7%) of HD, and 34 cases (of 132, 
25.8%) of OSCC (Figure 4E, 4J). Forty-one cases were recorded as 
HRM-positive or ambiguous, including four cases (of 15, 26.7%) of LP, two 
cases (of 15, 13.3%) of LD, one case (of 15, 6.7%) of HD, and 34 cases (of 132, 
25.8%) of OSCC (Figure 4A, 4B, 4F, 4G). A total of 41 positive or ambiguous 
cases, based on HRM, were subjected to sequencing to confirm the mutation. 
Seven mutation-positive cases were confirmed by direct sequencing, 
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including one case of LD, one case of HD, and five cases of OSCC (Figure 4C, 
4D, 4H, 4I). 
 
Correlations between DNA sequencing and IHC to detect BRAF mutations 
 The results of correlation analysis comparing IHC and molecular data are 
presented in Table V. All seven BRAF mutation-positive cases detected by 
direct DNA sequencing were also positive based on IHC, including two cases 
of OEPLs (weak positive) and five cases in OSCC (strong positive) (Table V). 
The correlations between IHC reactivity and DNA sequencing were 
significant for both OEPLs (P < .05) and OSCC (P < .001) (Table V). Further, 
the clinicopathological features of seven BRAF -mutated cases are presented 
in Table VI.  
 
 
DISCUSSION 
 
The oncogenic role of aberrant MAPK, Akt, and STAT3 signaling pathway 
activation has been investigated in various malignancies including head and 
neck cancer. The MAPK pathway regulates all critical phases of cell growth 
including proliferation, differentiation, and apoptosis, and deregulation of 
this pathway has been reported in several types of tumors.22  
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MAPK pathway 
In the present study, significant loss of KRAS and NRAS immunoreactivity 
was found in OSCC as compared to expression in OEPLs. Vairaktaris et al 
showed that the NRAS immunoreactivity decreased during the following 
stages of oncogenesis.12 In contrast, Jian et al have reported that the 
expression of RAS was undetectable in precancer lesions but was found in 
esophageal squamous cell carcinoma.28 These features suggest that KRAS 
and NRAS activation might represent a relatively early alteration in oral 
carcinogenesis. Previous studies have also demonstrated HRAS expression 
in normal, benign, dysplastic, and malignant lesions for bladder and breast 
cancer.29,30 In our study, HRAS expression was constitutively observed in 
OEPLs and OSCC, suggesting that its activation might have a role in oral 
carcinogenesis. In our study, BRAF immunoreactivity was found in most 
OEPLs and OSCC, whereas BRAF-V600E expression was not observed in no 
dysplastic leukoplakia but was detected in lesions with dysplastic changes, 
especially in OSCC. These results suggest that wild type BRAF functions in 
a constitutive manner during oral carcinogenesis and that the mutation of 
this protein gene might be limited to OSCC development. In the present 
study, pERK1/2 expression tended to increase in oral lesions with dysplastic 
changes including OSCC, as compared to that in tissues without dysplastic 
lesions, and was highest in HD. Chang et al showed that pERK1/2 
expression is low in normal cervical tissues, but is significantly higher in 
cervical intraepithelial neoplasia, when compared to that in cervical 
carcinoma, at both the transcriptional and translational levels.31 These 
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features suggest that pERK1/2 expression could be an early and potentially 
critical event during oral cancer development. 
We found that increased levels of KRAS and NRAS significantly correlate 
with age, male gender, and disease site. In addition, HRAS and BRAF 
expression tended to be higher in men than in women. Mahmoud et al also 
showed that KRAS immunoreactivity in tumor specimens tended to be 
higher in males than in females with colorectal carcinoma.13 We also 
confirmed that HRAS and BRAF immunoreactivity tended to increase with 
M classification, recurrence, lymph node metastasis, survival, and mode of 
invasion, suggesting that these markers might be involved in the 
progression and prognosis of OSCC. Several reports have indicated that 
BRAF mutations are associated with clinicopathological features including 
female gender, advanced stage, tumor location, lymph node metastasis, 
recurrence, and poor differentiation in colorectal and thyroid carcinoma.18,32 
Our data showed that BRAF-V600E reactivity tended to be slightly more 
frequent in males and with early stages of OSCC. We also found a 
significant association between BRAF-V600E reactivity and postoperative 
lymph node metastasis, as well as slightly higher BRAF-V600E expression 
in cases with grade 3, 4C, and 4D modes of invasion. These features suggest 
that BRAF mutations might be associated with the aggressive behavior of 
OSCC cells. Several reports have indicated that pERK1/2 is associated with 
clinicopathological features including cell proliferation, differentiation, 
survival, invasion, lymph node metastasis, and recurrence in HNSCC.8,19 
Wang et al reported that pERK1/2 expression is associated with T stage, 
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resulting in advanced TNM stage.33 In the present study, pERK1/2 
expression was higher in females than in males. In addition, we found that 
the expression of pERK1/2 in OSCC correlates with advanced TNM stage, 
and especially T classification, and that pERK1/2 expression tends to 
increase according to recurrence, postoperative lymph node metastasis, and 
patient death. These features suggest that this marker might be involved in 
the progression of OSCC. Further, pERK1/2 immunoreactivity tended to be 
higher with poor differentiation and advanced invasion depth, suggesting 
that it could be correlated with carcinoma cell differentiation and OSCC 
prognosis. 
 
BRAF mutations 
BRAF mutations result in constitutive activation of the encoded protein and 
its downstream MAPK pathway, which promotes proliferation and 
tumorigenesis. The detection of BRAF mutations has been reported using 
several different molecular techniques such as direct DNA sequencing, 
allele-specific real-time quantitative polymerase chain reaction, 
pyrosequencing, and HRM. HRM analysis is a recently developed molecular 
technique proven to be applicable for the detection of various clinically 
relevant mutations in humans. In addition, the PCR amplification products 
obtained from HRM analysis can be directly used for direct sequencing 
without pretreatment.34 Moreover, IHC using a BRAF-V600E specific 
antibody has been utilized to detect BRAF mutations in various tumors 
including malignant melanoma, thyroid carcinoma, and pulmonary 
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carcinoma.16 It was previously established that the immunohistochemical 
detection of mutant BRAF-V600E can be used in clinical practice as a first 
test to screen for BRAF mutations.17 In the present study, we used a 
combined strategy to screen mutations. All samples were first analyzed by 
HRM and IHC, and then suspected positive samples were subjected to direct 
DNA sequencing. We found that 2/45 (4.4%) OEPLs and 34/132 (25.8%) 
OSCCs were positive for BRAF-V600E by IHC, whereas 7/45 (15.6%) OEPLs 
and 34/132 (25.8%) OSCCs were positive or ambiguous for BRAF-V600E 
based on HRM. Regarding the detection of BRAF mutations, there was no 
prominent correlation between IHC and HRM. However, we revealed that 
IHC reactivity significantly correlated with BRAF mutations identified by 
direct DNA sequence. Thus, we confirmed that two weak-positive OEPL 
cases and five strong-positive OSCC cases, based on IHC, comprised BRAF 
mutant cases. Our results demonstrated that BRAF-V600E IHC could be 
useful for screening the mutational status of OSCC.  
BRAF mutations have been reported in several studies, and the mutation 
rates have ranged from 0% to 3% for HNSCC samples.14,15,35 In the present 
study, BRAF mutations were identified in five cases (3.8%) of OSCC samples 
and two cases (4.4%) of OEPLs samples. These OSCC cases predominantly 
included early stage disease, but included recurrent, metastatic, poorly 
differentiated, and grade 4C−D invasion cases. The frequency of mutations 
in OSCC and OEPLs was similar to that reported in other studies, 
suggesting that BRAF mutations are somewhat rare and that they represent 
a relatively early alteration in the oral mucosal epithelium. 
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Akt pathway   
Akt signaling is known to be frequently activated in human cancers.9, 21 In 
our study, pAkt expression in LP was detected predominantly in the 
cytoplasm of epithelial cells, whereas pmTOR was detected in the cytoplasm 
and nuclei. In LD, HD, and OSCC, pAkt and pmTOR were localized to the 
nuclei and cytoplasm of epithelial or carcinoma cells. Previous studies have 
shown variable distribution of pAkt in different cellular compartments of 
oral premalignant and malignant lesions, indicating that pAkt localization 
might be related to differences in activity.36,37 It has been reported that active 
Akt and mTOR localize mainly in the cytoplasm of tumor cells, although the 
ratio of nuclear to cytoplasmic reactivity was found to increase during tumor 
progression.38,39 Recent studies demonstrated that pAkt expression in OSCC 
is significantly increased when compared to that in the normal epithelium 
and epithelial dysplasia.36,37 Balsara et al reported that dysplastic lung 
tissue contains a high concentration of pAkt, which could further promote 
the malignant transformation of precancerous cells.20 Our analysis revealed 
significantly enhanced pAkt reactivity in OSCC compared to that in LP, and 
this tended to be lower in HD than in LD. In addition, pmTOR reactivity was 
significantly decreased in LP compared to that in LD, HD, and OSCC, but 
there was no apparent relationship among LD, HD, and OSCC, as observed 
by Martins et al.21 These features suggest that pAkt and pmTOR expression 
could contribute to an early and potentially critical event required for the 
progression from dysplastic lesions to oral cancer.  
In this study, increased expression of pAkt was significantly correlated with 
23 
 
advanced T stage and tended to be higher with M stage, differentiation, and 
invasion depth. In addition, we found that pAkt expression was significantly 
higher in tumors form patients with negative lymph node metastasis as 
compared to that in patients with positive lymph node metastasis. These 
results support previously studies on patients with gastric carcinomas and 
HNSCC.9,40 In contrast, Lim et al have indicated pAkt expression correlates 
with lymph node metastasis and clinical stage, which remains a significant 
prognostic factor for OSCC.41 We also confirmed that pAkt tended to increase 
with low differentiation and deep invasion. Hutchinson et al. reported that 
pAkt is closely associated with invasion and metastasis.42 These features 
suggest that pAkt might correlate with disease stage and could be a 
prognostic factor. In the present study, pmTOR overexpression was 
significantly correlated with advanced T stage, lymph node metastasis, and 
differentiation in OSCC.21,39 mTOR inhibition has been found to decrease cell 
migration and invasion depending on the cell system, thus indicating that its 
activation is correlated with cancer cell invasion and distant metastasis.43,44 
However, previous reports have also indicated that there is no significant 
correlation between pmTOR expression and any clinical factors for OSCC 
and lung cancer.10,22 The present data showed that increased expression of 
pmTOR was significantly correlated with mode of invasion. These features 
suggest that mTOR might play a role in the progression and morphologic 
characteristics of OSCC. 
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STAT3 pathway 
Increasing evidence supports the critical role of STAT3 in malignant 
transformation and tumor progression.11,23 Grandis et al. showed that 
pSTAT3 is detected only in the basal epithelial layer, based on a 
representative normal mucosal sample from a patient without cancer. In 
contrast, pSTAT3 is present throughout the entire epithelium in normal 
mucosal sections from cancer patients and is overexpressed in neoplastic 
regions.10 Muzafar et al. demonstrated that increased nuclear accumulation 
of pSTAT3 occurs during early premalignant stages and assumed that it is a 
predictor of poor prognosis in OSCC.4 In our study, OSCC samples showed 
intermediate nuclear and cytoplasmic pSTAT3 staining in most carcinoma 
cells as described previously, whereas OEPLs exhibited pSTAT3 reactivity in 
limited epithelial portions, suggesting that its participates in invasive 
growth. In the oral mucosa, STAT3 activation might occur as a relatively late 
event in carcinogenesis and could serves as a biomarker for invasiveness. 
Several reports have indicated that activated STAT3 is associated with 
clinicopathological features, including tumor stage, lymph node metastasis, 
recurrence, differentiation, and decreased survival in HNSCC.4,23,24 Neelam 
et al. revealed that in specimens from early-stage OSCC with nuclear STAT3 
immunoreactivity, patients are 3.23-times more likely to develop recurrence 
when compared to patients with early-stage disease devoid of STAT3 
immunoreactivity.24 In the present study, we found that increased pSTAT3 
levels significantly correlate with recurrence and invasion depth, and 
pSTAT3 reactivity tended to increase according to TNM stage, lymph node 
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metastasis, survival, differentiation degree, and mode of invasion. 
Cumulatively, our results suggest that STAT3 contributes to the aggressive 
behavior of cancers, and is related to poor prognosis in oral mucosal cancer 
and precancerous lesions; moreover, STAT3 signaling might represent a 
promising therapeutic target for head and neck cancer. 
 
 
CONCLUSION 
 
We analyzed the activation of growth factor downstream signaling 
molecules including MAPK, Akt, and STAT3 in OSCC and OEPLs, and this 
was compared to relevant clinicopathologic variables in OSCC. In addition, 
the correlation between BRAF-V600E gene mutations and product protein 
expression was investigated in these precancerous and malignant lesions. 
This resulted in the delineation of critical pathways involved in 
carcinogenesis, which could be exploited to direct pharmaceutical 
intervention. 
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Fig. 3. Representative hematoxylin-eosin staining (A−E) and immunohistochemical staining for pAkt (F−J), pmTOR (K−O),
and pSTAT3 (P−T) in leukoplakia (LP; A, F, K, P, ×200), low-grade epithelial dysplasia (LD; B, G, L, Q, ×200), high-grade
epithelial dysplasia (HD; C, H, M, R, ×400), well-differentiated squamous cell carcinoma (SCC-Well; D, I, N, S, ×200), and
moderately-differentiated  squamous cell carcinoma (SCC-Moderate; E, J, O, T, ×200). pAkt showed weak cytoplasmic
staining in epithelial cells (F). pAkt showed strong cytoplasmic and nuclear staining in the basal and prickle cell layers with
colocalization of pmTOR and pSTAT3 expression (G, H, L, M, Q, R). pmTOR showed moderate cytoplasmic and nuclear
staining in the basal and prickle cell layers (K). pSTAT3 showed strong cytoplasmic and nuclear staining in the basal and
prickle cell layers (P). pAkt and pmTOR showed moderate or strong cytoplasmic and nuclear staining in most carcinoma cells,
and pSTAT3 showed weak or moderate cytoplasmic and nuclear staining in most carcinoma cells (I, J, N, O, S, T).
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Fig. 2.  Representative hematoxylin-eosin staining (A−E) and immunohistochemical staining for  BRAF (F−J), BRAF-V600E
(K−O), and pERK1/2 (P−T) in leukoplakia (LP; A, F, K, P, ×200), low-grade epithelial dysplasia (LD; B, G, L, Q, ×200), high-
grade epithelial dysplasia (HD; C, H, M, R, ×400), well-differentiated squamous cell carcinoma (SCC-Well; D, I, N, S, ×200),
and moderately-differentiated squamous cell carcinoma (SCC-Moderate; E, J, O, T, ×200). BRAF showed moderate or strong
cytoplasmic staining in the basal and prickle cell layers and most carcinoma cells (F−J). BRAF-V600E showed negative
expression (K−M). BRAF-V600E showed moderate or strong cytoplasmic staining in most carcinoma cells (N, O). pERK1/2
showed moderate or strong cytoplasmic and nuclear staining in the basal and prickle cell layers (P). pERK1/2 showed strong
cytoplasmic and nuclear staining in the basal and prickle cell layers (Q, R). pERK1/2 showed moderate or strong cytoplasmic
and nuclear staining in most carcinoma cells (I, J, S, T).
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Fig. 1. Representative hematoxylin-eosin staining (A−E) and immunohistochemical staining for KRAS (F−J), HRAS (K−O),
and NRAS (P−T) in leukoplakia (LP; A, F, K, P, ×200), low-grade epithelial dysplasia (LD; B, G, L, Q, ×200), high-grade
epithelial dysplasia (HD; C, H, M, R, ×400), well-differentiated squamous cell carcinoma (SCC-Well; D, I, N, S, ×200), and
moderately-differentiated squamous cell carcinoma (SCC-Moderate; E, J, O, T, ×200). KRAS showed moderate or strong
cytoplasmic staining with occasional membrane reactivity in epithelial cells (F−H). KRAS showed weak or moderate
cytoplasmic staining in most carcinoma cells (I, J). HRAS and NRAS showed moderate or strong cytoplasmic staining in the
basal cell and parabasal cell layers (K−M, P−R). HRAS and NRAS showed moderate or strong cytoplasmic staining in most
carcinoma cells (N, O, S, T）.
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Fig. 4. Detection of BRAF mutations in patients with high-grade epithelial dysplasia (A−E) and well-differentiated
squamous cell carcinoma (F−J) using high resolution melting (HRM) analysis, direct DNA sequence, and
immunohistochemistry (IHC). The normalized high-resolution melting curves showed left-shifted curves in mutant samples
(A, F). The temperature-shifted difference plots of each tested sample were subtracted from the reference curves obtained by
analyzing control, wild type BRAF  sequences (B, G). Sequencing results confirmed the presence of the BRAF  mutations
(T1799A) using forward (C, H) and reverse (D, I) primers. A BRAF-V600E IHC assay revealed weak expression in the prickle
cell layer of an epithelial dysplasia specimen(E, ×200) and strong expression in most carcinoma cells from a squamous cell
carcinoma specimen (J, ×200).
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 Table I. Immunohistochemical reactivity for KRAS, HRAS, NRAS, BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 in oral epithelial precursor lesions and squamous cell carcinoma
Number of cases
177 ＋ ＋＋ ＋ ＋＋ ＋ ＋＋ ＋ ＋＋ － ± ＋ ＋ ＋＋ ＋ ＋＋ ＋ ＋＋ ＋ ＋＋
Leukoplakia without epithelial dysplasia （LP)
(Squamous cell hyperplasia)
15 2 (13.3%) 13 (86.7%) 0 (0%) 15 (100%) 0 (0%) 15 (100%) 0 (0%) 15 (100%) 15 (100%) 0 (0%) 0 (0%) 5 (33.3%) 10 (66.7%) 10 (66.7%) 5 (33.3%) 8 (53.3%) 7 (46.7%) 0 (0%) 15 (100%)
Low-grade epithelial dysplasia (LD)
(Mild to moderate epithelial dysplasia)
15 3 (20.0%) 12 (80.0%) 0 (0%) 15 (100%) 0 (0%) 15 (100%) 1 (6.7%) 14 (93.3%) 14 (93.3%) 1 (6.7%) 0 (0%) 2 (13.3%) 13 (86.7%) 4 (26.7%) 11 (73.3%) 0 (0%) 15 (100%) 0 (0%) 15 (100%)
High-grade epithelial dysplasia (HD)
(Moderate to Severe epithelial dysplasia)
15 0 (0%) 15 (100%) 0 (0%) 15 (100%) 0 (0%) 15 (100%) 1 (6.7%) 14 (93.3%) 14 (93.3%) 1 (6.7%) 0 (0%) 0 (0%) 15 (100%) 7 (46.7%) 8 (53.3%) 0 (0%) 15 (100%) 0 (0%) 15 (100%)
Squamous cell carcinoma (SCC) 132 95 (72.0%) 37 (28.0%) 9 (6.8%) 123 (93.2%) 65 (49.2%) 67 (50.8%) 5 (3.8%) 127 (96.2%) 98 (74.2%) 29 (22.0%) 5 (3.8%) 16 (12.1%) 116 (87.9%) 33 (25.0%) 99 (75.0%) 9 (6.8%) 123 (93.2%) 16 (12.1%) 116 (87.9%)
Immunoreactivity except for BRAF-V600E 
(++): strongly positive (strongly reactive as compared with adjacent normal part)
BRAF-V600E immunoreactivity
(‒) : negative (no staining or only nuclear dot staining)
(±) : weak positive or ambiguous (immunostaining could not be evaluated as positive or negative)
(+) : positive (clear cytoplasmic staining)
Statistical significance
*P < 0.05
**P  < 0.01
***P < 0.001
BRAF-V600E pERK1/2
(+)  : positive (reactive at the same level as adjacent normal part)
pAkt pmTOR pSTAT3KRAS HRAS NRAS BRAF
Number of cases
132 ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value － ± ＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value
20-29 2 2 0 <.001 1 1 .060 2 0 <.001 0 2 .590 1 1 0 .437 0 2 .292 1 1 .447 0 2 .184 0 2 .169
30-39 3 3 0 0 3 2 1 0 3 2 1 0 0 3 0 3 0 3 0 3
40-49 15 14 1 1 14 6 9 0 15 10 5 0 0 15 6 9 0 15 0 15
50-59 17 11 6 2 15 15 2 2 15 13 3 1 0 17 3 14 1 16 2 15
60-69 30 26 4 1 29 21 9 2 28 27 2 1 5 25 8 22 2 28 8 22
70-79 39 34 5 2 37 19 20 1 38 28 9 2 8 31 11 28 1 38 5 34
80-89 24 5 19 1 23 0 24 0 24 15 8 1 3 21 3 21 5 19 1 23
90-99 2 0 2 1 1 0 2 0 2 2 0 0 0 2 1 1 0 2 0 2
M 70 42 28 <.001 5 65 .060 23 47 <.001 1 69 .067 53 12 5 .440 12 58 .031 19 51 .275 6 64 .195 7 63 .216
F 62 53 9 4 58 42 20 4 58 45 17 0 4 58 14 48 3 59 9 53
Tongue 71 43 28 .029 5 66 .237 24 47 .012 1 70 .139 49 20 2 .424 12 59 .122 17 54 .534 6 65 .514 7 64 .002
Upper gingiva 11 11 0 0 11 8 3 2 9 8 2 1 1 10 1 10 0 11 2 9
Lower gingiva 24 18 6 1 23 18 6 2 22 18 4 2 0 24 5 19 1 23 2 22
Hard palate 2 1 1 0 2 1 1 0 2 2 0 0 0 2 1 1 0 2 2 0
Buccal mucosa 11 10 1 0 11 6 5 0 11 8 3 0 0 11 5 6 0 11 0 11
Floor of mouth 10 9 1 2 8 6 4 0 10 10 0 0 3 7 3 7 2 8 3 7
Lower lip 3 3 0 1 2 2 1 0 3 3 0 0 0 3 1 2 0 3 0 3
1 40 27 13 .507 2 38 .842 15 25 .296 3 37 .357 28 8 4 .711 5 35 .012 9 31 .056 4 36 .689 6 34 .618
2 41 33 8 4 37 24 17 1 40 30 10 1 10 31 16 25 3 38 6 35
3 17 11 6 1 16 9 8 1 16 13 4 0 1 16 4 13 1 16 2 15
4 34 24 10 2 32 17 17 0 34 27 7 0 0 34 4 30 1 33 2 32
0 100 71 29 .899 7 93 .916 50 50 .582 4 96 .527 73 22 5 .309 16 84 .122 28 72 .279 8 92 .542 14 86 .596
1 9 7 2 1 8 3 6 1 8 5 4 0 0 9 0 9 1 8 0 9
2 22 16 6 1 21 11 11 0 22 19 3 0 0 22 5 17 0 22 2 20
3 1 1 0 0 1 1 0 0 1 1 0 0 0 1 0 1 0 1 0 1
0 126 89 37 .060 9 117 .254 61 65 .194 5 121 .316 92 29 5 .073 16 110 .179 30 96 .076 9 117 .254 16 110 .179
1 6 6 0 0 6 4 2 0 6 6 0 0 0 6 3 3 0 6 0 6
Ⅰ 36 24 12 .297 2 34 .764 15 21 .570 3 33 .292 26 6 4 .537 5 31 .004 8 28 .097 4 32 .469 6 30 .432
Ⅱ 38 31 7 4 34 22 16 1 37 28 9 1 10 28 15 23 2 36 6 32
Ⅲ 20 12 8 1 19 10 10 1 19 13 7 0 1 19 4 16 2 18 1 19
Ⅳ 38 28 10 2 36 18 20 0 38 31 7 0 0 38 6 32 1 37 3 35
Negative 113 83 30 .180 9 104 .103 58 55 .123 5 108 .178 83 26 4 .331 15 98 .163 30 83 .160 9 104 .103 16 97 .041
Positive 19 12 7 0 19 7 12 0 19 15 3 1 1 18 3 16 0 19 0 19
Negative 116 82 34 .191 8 108 .465 58 58 .322 5 111 .199 89 24 3 .030 15 101 .224 26 90 .033 8 108 .465 13 103 .196
Positive 16 13 3 1 15 7 9 0 16 9 5 2 1 15 7 9 1 15 3 13
Alive 108 78 30 .450 7 101 .424 55 53 .130 3 105 .288 80 23 5 .297 13 95 .195 26 82 .419 9 99 .098 15 93 .150
Dead 19 14 5 1 18 7 12 1 18 15 4 0 1 18 5 14 0 19 1 18
Dead of
other disease
2 1 1 1 1 1 1 0 2 0 2 0 1 1 1 1 0 2 0 2
Unknown 3 2 1 0 3 2 1 1 2 3 0 0 1 2 1 2 0 3 0 3
Immunoreactivity except for BRAF-V600E
 (‒)   : negative
 (+)   : positive (reactive at the same level as adjacent normal part)
 (++) : strongly positive (strongly reactive as compared with adjacent normal part)
BRAF-V600E immunoreactivity
 (‒) : negative (no staining or only nuclear dot staining)
 (±) : weak positive or ambiguous (immunostaining could not be evaluated as positive or negative)
 (+) : positive (clear cytoplasmic staining)
Statistical significance
*P < 0.05
**P  < 0.01
***P < 0.001
Postoperative
metastasis
(regional lymph node)
Survival
Site
T classification
N classification
M classification
TNM Stage
Recurrence
Age
Sex
KRAS HRAS NRAS BRAF BRAF-V600E
Table II. Correlation between clinical variables and immunoreactivity for  KRAS, HRAS, NRAS, BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 in oral squamous cell carcinoma
pERK1/2 pAkt pmTOR pSTAT3
Number of cases
132 ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value － ± ＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value ＋ ＋＋ P value
Well 110 77 33 .503 7 103 .342 54 56 .997 5 105 .597 80 28 2 .767 16 94 .164 26 84 .195 8 102 .182 16 94 .164
Moderate 18 15 3 1 17 9 9 0 18 15 1 2 0 18 7 11 0 18 0 18
Poor 4 3 1 1 3 2 2 0 4 3 0 1 0 4 0 4 1 3 0 4
Slight 12 9 3 .767 2 10 .349 6 6 .998 1 11 .669 8 4 0 .663 2 10 .774 5 7 .283 1 11 .910 2 10 .219
Moderate 118 85 33 7 111 58 60 4 114 89 24 5 14 104 28 90 8 110 13 105
Severe 2 1 1 0 2 1 1 0 2 1 1 0 0 2 0 2 0 2 1 1
2 17 14 3 .112 1 16 .377 10 7 .091 1 16 .927 12 5 0 .483 2 15 .605 4 13 .520 0 17 .020 3 14 .582
3 85 60 25 8 77 43 42 3 82 65 17 3 12 73 22 63 7 78 9 76
4C 24 19 5 0 24 12 12 1 23 18 5 1 1 23 7 17 0 24 4 20
4D 6 2 4 0 6 0 6 0 6 3 2 1 1 5 0 6 2 4 0 6
Microinvasion 36 27 9 .785 4 32 .426 20 16 .335 2 34 .737 26 9 1 .282 7 29 .064 13 23 .195 2 34 .358 9 27 .021
Mucosal tissue 51 35 16 2 49 21 30 2 49 42 6 3 2 49 11 40 2 49 4 47
Submucosal tissue 45 33 12 3 42 24 21 1 44 30 14 1 7 38 9 36 5 40 3 42
Immunoreactivity except for BRAF-V600E 
 (–)  : negative
 (+)  : positive (reactive at the same level as adjacent normal part)
(++) : strongly positive (strongly reactive as compared with adjacent normal part)
BRAF-V600E immunoreactivity
 (–) : negative (no staining or only nuclear dot staining)
 (±) : weak positive or ambiguous (immunostaining could not be evaluated as positive or negative)
 (+) : positive (clear cytoplasmic staining)
Statistical significance
*P < 0.05
Invasion depth
pAkt pmTOR pSTAT3
Degree of defferentiation
Stromal lymphocytic reaction
Mode of invasion
Table III. Correlation between pathological variables and immunoreactivity for KRAS, HRAS, NRAS, BRAF, BRAF-V600E, pERK1/2, pAkt, pmTOR, and pSTAT3 in oral squamous cell carcinoma
KRAS HRAS NRAS BRAF BRAF-V600E pERK1/2
 Table IV. Correlation of detected BRAF  mutations among  IHC, HRM, direct DNA sequencing, and in oral epithelial precursor lesions and squamous cell carcinoma
Total – ± + P value Total Wild
Mutant or
ambiguous
P value Total Wild Mutant P value
Leukoplakia without epithelial dysplasia （LP)
(Squamous cell hyperplasia)
15 15 0 0 .093 15 11 4 .297 4 4 0 .067
Low-grade epithelial dysplasia (LD)
(Mild to moderate epithelial dysplasia)
15 14 1 0 15 13 2 2 1 1
High-grade epithelial dysplasia (HD)
(Moderate to Severe epithelial dysplasia)
15 14 1 0 15 14 1 1 0 1
Squamous cell carcinoma (SCC) 132 98 29 5 132 98 34 34 29 5
IHC SequenceHRM
IHC, Immunohistochemistry; HRM, High resolution melting
 Table V. Correlation of detected BRAF  mutations between IHC and direct DNA sequencing in oral epithelial precursor lesions and squamous cell carcinoma
Wild Mutant Total P value Wild Mutant Total P value
– 5 0 5 .014 11 0 11 <.001
± 0 2 2 18 0 18
+ 0 0 0 0 5 5
Total 5 2 7 29 5 34
Statistical significance
*P < 0.05
***P < 0.001
Sequence
IHC
OEPLs SCC
IHC, Immunohistochemistry; OEPLs, Oral epithelial precursor lesions
Case
Age
(Year)
Sex Site TNM classification TNM Stage Recurrence
Postoperative metastasis
(regional lymph node)
Survival Degree of defferentiation Stromal lymphocytic reaction Mode of invasion Invasion depth
LD 79 M Upper gingiva
HD 61 F Tongue
SCC 57 M Tongue T1N0M0 Ⅰ Yes Yes Alive Moderate Moderate 4C Submucosal tissue
SCC 60 M Lower gingiva T2N0M0 Ⅱ No Yes Alive Low Moderate 4D Mucosal tissue
SCC 70 M Tongue T1N0M0 Ⅰ No No Alive Well Moderate 3 Mucosal tissue
SCC 77 M Lower gingiva T1N0M0 Ⅰ Yes No Alive Well Moderate 3 Microinvasion
SCC 81 M Upper gingiva T1N0M0 Ⅰ No No Alive Moderate Moderate 3 Mucosal tissue
 IHC, Immunohistochemistry; LD, Low-grade epithelial dysplasia (Mild to moderate epithelial dysplasia); HD, High-grade epithelial dysplasia (Moderate to Severe epithelial dysplasia); SCC, Squamous cell carcinoma. 
 
Table VI. List of cases of detected BRAF  mutations by both molecular assays and  IHC
 
 
